NSMAF
gene geneOn this page
Also known as FANGRAMD5
Summary
NSMAF (neutral sphingomyelinase activation associated factor, HGNC:8017) is a protein-coding gene on chromosome 8q12.1, encoding Protein FAN (Q92636). Couples the p55 TNF-receptor (TNF-R55 / TNFR1) to neutral sphingomyelinase (N-SMASE).
This gene encodes a WD-repeat protein that binds the cytoplasmic sphingomyelinase activation domain of the 55kD tumor necrosis factor receptor. This protein is required for TNF-mediated activation of neutral sphingomyelinase and may play a role in regulating TNF-induced cellular responses such as inflammation. Alternative splicing results in multiple transcript variants.
Source: NCBI Gene 8439 — RefSeq curated summary.
At a glance
- GWAS associations: 3
- Clinical variants (ClinVar): 162 total
- MANE Select transcript:
NM_003580
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:8017 |
| Approved symbol | NSMAF |
| Name | neutral sphingomyelinase activation associated factor |
| Location | 8q12.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FAN, GRAMD5 |
| Ensembl gene | ENSG00000035681 |
| Ensembl biotype | protein_coding |
| OMIM | 603043 |
| Entrez | 8439 |
Gene structure
Transcript identifiers
Ensembl transcripts: 27 — 11 protein_coding, 10 retained_intron, 3 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined
ENST00000038176, ENST00000427130, ENST00000517612, ENST00000518159, ENST00000518229, ENST00000519166, ENST00000519174, ENST00000519227, ENST00000519858, ENST00000519871, ENST00000521712, ENST00000521972, ENST00000522645, ENST00000523106, ENST00000523177, ENST00000523982, ENST00000524148, ENST00000649465, ENST00000870782, ENST00000870783, ENST00000870784, ENST00000958101, ENST00000958102, ENST00000958103, ENST00000958104, ENST00000958105, ENST00000958106
RefSeq mRNA: 21 — MANE Select: NM_003580
NM_001144772, NM_001412988, NM_001412989, NM_001412990, NM_001412991, NM_001412992, NM_001412993, NM_001412994, NM_001412995, NM_001412996, NM_001412997, NM_001412998, NM_001412999, NM_001413000, NM_001413001, NM_001413002, NM_001413003, NM_001413004, NM_001413005, NM_001413006, NM_003580
CCDS: CCDS47864, CCDS6173
Canonical transcript exons
ENST00000038176 — 31 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000980418 | 58586458 | 58586608 |
| ENSE00000980420 | 58585898 | 58586000 |
| ENSE00000980422 | 58585652 | 58585761 |
| ENSE00001118242 | 58623377 | 58623424 |
| ENSE00001118254 | 58601285 | 58601348 |
| ENSE00001118256 | 58623709 | 58623780 |
| ENSE00001198048 | 58659573 | 58659853 |
| ENSE00001242078 | 58583508 | 58584200 |
| ENSE00003463129 | 58597387 | 58597550 |
| ENSE00003473113 | 58597860 | 58597902 |
| ENSE00003502904 | 58595560 | 58595659 |
| ENSE00003531110 | 58587618 | 58587701 |
| ENSE00003533760 | 58590007 | 58590074 |
| ENSE00003541433 | 58607769 | 58607840 |
| ENSE00003544982 | 58602058 | 58602137 |
| ENSE00003571254 | 58635305 | 58635372 |
| ENSE00003576991 | 58631496 | 58631546 |
| ENSE00003578977 | 58601445 | 58601535 |
| ENSE00003579085 | 58599232 | 58599363 |
| ENSE00003587686 | 58589452 | 58589575 |
| ENSE00003588704 | 58599750 | 58599870 |
| ENSE00003598613 | 58623220 | 58623272 |
| ENSE00003611104 | 58642984 | 58643073 |
| ENSE00003621043 | 58635189 | 58635225 |
| ENSE00003635790 | 58603210 | 58603386 |
| ENSE00003647099 | 58635468 | 58635546 |
| ENSE00003647965 | 58609604 | 58609733 |
| ENSE00003659268 | 58590867 | 58590934 |
| ENSE00003663569 | 58605927 | 58606035 |
| ENSE00003673482 | 58599970 | 58600021 |
| ENSE00003683707 | 58594232 | 58594290 |
Expression profiles
Bgee: expression breadth ubiquitous, 294 present calls, max score 95.80.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.8803 / max 920.7762, expressed in 1819 samples.
FANTOM5 promoters (23 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 93214 | 16.4818 | 1804 |
| 93213 | 3.7789 | 1625 |
| 93199 | 3.1577 | 127 |
| 93195 | 2.2202 | 88 |
| 93211 | 2.2191 | 1195 |
| 93212 | 1.1481 | 747 |
| 93197 | 0.7881 | 121 |
| 93201 | 0.7470 | 105 |
| 93209 | 0.7092 | 403 |
| 93196 | 0.5883 | 86 |
Top tissues by expression
298 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| gingival epithelium | UBERON:0001949 | 95.80 | gold quality |
| tibia | UBERON:0000979 | 95.72 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 95.58 | gold quality |
| calcaneal tendon | UBERON:0003701 | 95.06 | gold quality |
| squamous epithelium | UBERON:0006914 | 94.96 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 94.73 | gold quality |
| stromal cell of endometrium | CL:0002255 | 94.53 | gold quality |
| visceral pleura | UBERON:0002401 | 94.48 | gold quality |
| gingiva | UBERON:0001828 | 94.36 | gold quality |
| choroid plexus epithelium | UBERON:0003911 | 94.27 | gold quality |
| skin of hip | UBERON:0001554 | 94.25 | gold quality |
| parietal pleura | UBERON:0002400 | 94.05 | gold quality |
| pleura | UBERON:0000977 | 93.99 | gold quality |
| body of pancreas | UBERON:0001150 | 93.91 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 93.82 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 93.68 | gold quality |
| superficial temporal artery | UBERON:0001614 | 93.49 | gold quality |
| tonsil | UBERON:0002372 | 93.44 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 93.33 | gold quality |
| adrenal tissue | UBERON:0018303 | 93.32 | gold quality |
| periodontal ligament | UBERON:0008266 | 93.22 | gold quality |
| monocyte | CL:0000576 | 93.11 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 93.06 | gold quality |
| skin of abdomen | UBERON:0001416 | 93.06 | gold quality |
| leukocyte | CL:0000738 | 93.01 | gold quality |
| blood | UBERON:0000178 | 93.00 | gold quality |
| mononuclear cell | CL:0000842 | 92.99 | gold quality |
| granulocyte | CL:0000094 | 92.88 | gold quality |
| skin of leg | UBERON:0001511 | 92.76 | gold quality |
| rectum | UBERON:0001052 | 92.71 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 5.82 |
| E-GEOD-100618 | no | 230.32 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
48 targeting NSMAF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-32-5P | 99.98 | 75.21 | 1964 |
| HSA-MIR-363-3P | 99.98 | 74.72 | 1821 |
| HSA-MIR-367-3P | 99.98 | 74.83 | 1819 |
| HSA-MIR-92A-3P | 99.98 | 75.21 | 1960 |
| HSA-MIR-92B-3P | 99.98 | 75.25 | 1955 |
| HSA-MIR-25-3P | 99.98 | 74.60 | 1817 |
| HSA-MIR-548AA | 99.96 | 70.64 | 3753 |
| HSA-MIR-548AP-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-548T-3P | 99.96 | 70.64 | 3753 |
| HSA-MIR-6768-5P | 99.92 | 67.36 | 1942 |
| HSA-MIR-5582-3P | 99.86 | 72.48 | 4221 |
| HSA-MIR-659-3P | 99.85 | 70.69 | 1620 |
| HSA-MIR-3121-3P | 99.82 | 71.96 | 3630 |
| HSA-MIR-6756-5P | 99.82 | 67.97 | 2466 |
| HSA-MIR-6745 | 99.74 | 65.33 | 1321 |
| HSA-MIR-6766-5P | 99.68 | 67.70 | 2325 |
| HSA-MIR-7-5P | 99.67 | 70.53 | 1809 |
| HSA-MIR-7157-5P | 99.66 | 69.33 | 1829 |
| HSA-MIR-1303 | 99.65 | 69.77 | 1662 |
| HSA-MIR-586 | 99.65 | 70.40 | 2051 |
| HSA-MIR-5700 | 99.64 | 69.88 | 2280 |
| HSA-MIR-497-3P | 99.61 | 69.71 | 1990 |
| HSA-MIR-4310 | 99.59 | 68.84 | 2527 |
| HSA-MIR-18A-3P | 99.56 | 65.68 | 1092 |
| HSA-MIR-4672 | 99.50 | 71.58 | 2893 |
| HSA-MIR-3123 | 99.47 | 67.15 | 2693 |
| HSA-MIR-363-5P | 99.46 | 64.51 | 1015 |
| HSA-MIR-5589-3P | 99.29 | 68.30 | 1443 |
| HSA-MIR-892C-5P | 99.16 | 70.56 | 2116 |
| HSA-MIR-10B-3P | 99.04 | 66.98 | 988 |
Literature-anchored findings (GeneRIF, showing 5)
- The interaction of FAN with receptor for activated C-kinase 1 (RACK1) appears to be dependent on the folding of the WD repeats into a secondary structure, because no linear binding motifs are identified in the WD-repeat region of FAN. (PMID:12391233)
- sphingolipid activator proteins like domain may stabilize the fold of acid sphingomyelinase (PMID:15653433)
- Regulation of NSMAF by TNF-alpha involves PRKCD in lung epithelial cells. (PMID:18653803)
- The rs1050504 C > T genotype was observed to be significantly associated with an increased risk for developing pulmonary tuberculosis. (PMID:29115933)
- these data identify a novel caspase-2-interacting factor, FAN, and expand the role for the enzyme in seemingly non-apoptotic cellular mechanisms. (PMID:29621545)
Cross-species orthologs
5 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | nsmaf | ENSDARG00000051920 |
| mus_musculus | Nsmaf | ENSMUSG00000028245 |
| rattus_norvegicus | Nsmaf | ENSRNOG00000010234 |
| caenorhabditis_elegans | WBGENE00004760 | |
| caenorhabditis_elegans | WBGENE00007752 |
Paralogs (7): WDFY4 (ENSG00000128815), LYST (ENSG00000143669), NBEAL1 (ENSG00000144426), NBEAL2 (ENSG00000160796), WDFY3 (ENSG00000163625), NBEA (ENSG00000172915), LRBA (ENSG00000198589)
Protein
Protein identifiers
Protein FAN — Q92636 (reviewed: Q92636)
Alternative names: Factor associated with neutral sphingomyelinase activation
All UniProt accessions (3): E5RGF5, E5RGU2, Q92636
UniProt curated annotations — full annotation on UniProt →
Function. Couples the p55 TNF-receptor (TNF-R55 / TNFR1) to neutral sphingomyelinase (N-SMASE). Specifically binds to the N-smase activation domain of TNF-R55. May regulate ceramide production by N-SMASE.
Tissue specificity. Ubiquitous.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q92636-1 | 1 | yes |
| Q92636-2 | 2 |
RefSeq proteins (21): NP_001138244, NP_001399917, NP_001399918, NP_001399919, NP_001399920, NP_001399921, NP_001399922, NP_001399923, NP_001399924, NP_001399925, NP_001399926, NP_001399927, NP_001399928, NP_001399929, NP_001399930, NP_001399931, NP_001399932, NP_001399933, NP_001399934, NP_001399935, NP_003571* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000409 | BEACH_dom | Domain |
| IPR001680 | WD40_rpt | Repeat |
| IPR004182 | GRAM | Domain |
| IPR011993 | PH-like_dom_sf | Homologous_superfamily |
| IPR015943 | WD40/YVTN_repeat-like_dom_sf | Homologous_superfamily |
| IPR023362 | PH-BEACH_dom | Domain |
| IPR036322 | WD40_repeat_dom_sf | Homologous_superfamily |
| IPR036372 | BEACH_dom_sf | Homologous_superfamily |
| IPR050865 | BEACH_Domain | Family |
| IPR057496 | FAN-like_PH | Domain |
Pfam: PF00400, PF02138, PF02893, PF25400
UniProt features (13 total): repeat 6, domain 3, chain 1, splice variant 1, sequence variant 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q92636-F1 | 88.46 | 0.71 |
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-5626978 | TNFR1-mediated ceramide production |
MSigDB gene sets: 194 (showing top):
GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, GOBP_RESPONSE_TO_PEPTIDE, GTGCCTT_MIR506, ONKEN_UVEAL_MELANOMA_UP, GOBP_SPHINGOLIPID_METABOLIC_PROCESS, MARTINEZ_RB1_TARGETS_DN, PID_TNF_PATHWAY, GOBP_AMIDE_METABOLIC_PROCESS, LIAO_METASTASIS, GOBP_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON, GOBP_LIPID_METABOLIC_PROCESS, GOBP_CERAMIDE_METABOLIC_PROCESS
GO Biological Process (6): ceramide metabolic process (GO:0006672), signal transduction (GO:0007165), tumor necrosis factor-mediated signaling pathway (GO:0033209), obsolete positive regulation of amide metabolic process (GO:0034250), positive regulation of lipid metabolic process (GO:0045834), obsolete regulation of membrane lipid metabolic process (GO:1905038)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| TNF signaling | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| sphingolipid metabolic process | 1 |
| cell communication | 1 |
| cellular process | 1 |
| signaling | 1 |
| regulation of cellular process | 1 |
| cellular response to stimulus | 1 |
| cytokine-mediated signaling pathway | 1 |
| cellular response to tumor necrosis factor | 1 |
| lipid metabolic process | 1 |
| positive regulation of metabolic process | 1 |
| regulation of lipid metabolic process | 1 |
| binding | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
Protein interactions and networks
STRING
1050 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| NSMAF | SMPD2 | O60906 | 917 |
| NSMAF | TNFRSF1A | P19438 | 864 |
| NSMAF | FAM110B | Q8TC76 | 591 |
| NSMAF | UBXN2B | Q14CS0 | 565 |
| NSMAF | RACK1 | P25388 | 564 |
| NSMAF | ARMC6 | Q6NXE6 | 465 |
| NSMAF | SDR16C5 | Q8N3Y7 | 426 |
| NSMAF | SMPD3 | Q9NY59 | 398 |
| NSMAF | BRINP1 | O60477 | 397 |
| NSMAF | PLCXD2 | Q0VAA5 | 397 |
| NSMAF | TMEM68 | Q96MH6 | 390 |
| NSMAF | BPNT2 | Q9NX62 | 381 |
| NSMAF | PRKACA | P17612 | 381 |
| NSMAF | PRKACB | P22694 | 380 |
| NSMAF | PRKACG | P22612 | 379 |
IntAct
34 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| HEXIM1 | CCNT1 | psi-mi:“MI:0914”(association) | 0.930 |
| NSMAF | GABARAPL1 | psi-mi:“MI:0407”(direct interaction) | 0.720 |
| GABARAPL1 | IPO5 | psi-mi:“MI:0914”(association) | 0.590 |
| NSMAF | DCP1B | psi-mi:“MI:0407”(direct interaction) | 0.530 |
| DCP1A | NSMAF | psi-mi:“MI:0915”(physical association) | 0.530 |
| NSMAF | psi-mi:“MI:0915”(physical association) | 0.530 | |
| DCP1B | NSMAF | psi-mi:“MI:0915”(physical association) | 0.530 |
| NSMAF | psi-mi:“MI:0407”(direct interaction) | 0.530 | |
| DCP1A | NSMAF | psi-mi:“MI:0407”(direct interaction) | 0.530 |
| NSMAF | DUSP14 | psi-mi:“MI:0914”(association) | 0.530 |
| NSMAF | GABARAP | psi-mi:“MI:0407”(direct interaction) | 0.520 |
| VASP | NSMAF | psi-mi:“MI:0915”(physical association) | 0.500 |
| ACTB | NSMAF | psi-mi:“MI:0915”(physical association) | 0.500 |
| NSMAF | VASP | psi-mi:“MI:0914”(association) | 0.500 |
| NSMAF | GABARAPL2 | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| NSMAF | MAP1LC3B | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| MAP1LC3C | NSMAF | psi-mi:“MI:0407”(direct interaction) | 0.440 |
| TNFRSF1A | NSMAF | psi-mi:“MI:0915”(physical association) | 0.400 |
| NSMAF | EPB41L2 | psi-mi:“MI:0914”(association) | 0.350 |
| NEK4 | E2F8 | psi-mi:“MI:0914”(association) | 0.350 |
| GABARAPL1 | GABARAP | psi-mi:“MI:0914”(association) | 0.350 |
| MAP1LC3A | psi-mi:“MI:0914”(association) | 0.350 | |
| GABARAPL1 | psi-mi:“MI:0914”(association) | 0.350 | |
| GABARAP | psi-mi:“MI:0914”(association) | 0.350 | |
| NSMAF | XIRP2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (69): NSMAF (Affinity Capture-MS), GNB2L1 (Two-hybrid), NSMAF (Affinity Capture-Western), CCT6A (Affinity Capture-MS), EPB41L2 (Affinity Capture-MS), PFDN2 (Affinity Capture-MS), TCP1 (Affinity Capture-MS), CCT3 (Affinity Capture-MS), CCT7 (Affinity Capture-MS), CCT4 (Affinity Capture-MS), CCT2 (Affinity Capture-MS), CCT8 (Affinity Capture-MS), CCT5 (Affinity Capture-MS), FBXL19 (Affinity Capture-MS), DOCK8 (Affinity Capture-MS)
ESM2 similar proteins: A0A0G2K344, D3ZGS3, F1M386, F1MSG6, F1PBJ0, G5EF51, O00329, O02697, O35242, O35904, O70481, O88763, O94830, P32871, P42336, P42337, P42338, P42339, P42347, P42348, P48736, P50520, P54676, P70600, Q01968, Q14289, Q14BI7, Q16JS8, Q3MHU3, Q3UYK3, Q4KWH5, Q4KWH8, Q5D891, Q5ZI89, Q6AZN6, Q6GQ76, Q6NVF0, Q6PF93, Q7Z392, Q80Y98
Diamond homologs: A8XSV3, D4A929, E7FAW3, E9Q2M9, F4HZB2, F4IG73, F4JD14, F4JHT3, O35242, P0C6P0, P25356, P50851, P97412, Q19317, Q54PP7, Q54RQ8, Q55AV3, Q55DM1, Q562E7, Q5ND34, Q6VNB8, Q6ZNJ1, Q6ZQA0, Q6ZS30, Q6ZS81, Q7LKZ7, Q86JF2, Q8IZQ1, Q8NFP9, Q92636, Q99698, Q9DDD5, Q9EPN1, Q9ESE1, Q9TTK4, Q9W060, Q9W4E2, E7FEV0, F4JY12, Q10122
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 23 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Macroautophagy | 6 | 34.6× | 2e-06 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| autophagosome maturation | 6 | 95.8× | 2e-09 |
| mitophagy | 6 | 86.7× | 3e-09 |
| autophagosome assembly | 6 | 61.3× | 2e-08 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
162 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 115 |
| Likely benign | 2 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
4504 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 8:58585646:GCTTA:G | donor_loss | 1.0000 |
| 8:58585647:CTTA:C | donor_loss | 1.0000 |
| 8:58585648:TTACC:T | donor_loss | 1.0000 |
| 8:58585649:TA:T | donor_loss | 1.0000 |
| 8:58586481:ACAAT:A | donor_gain | 1.0000 |
| 8:58586482:CAATC:C | donor_gain | 1.0000 |
| 8:58586486:C:A | donor_gain | 1.0000 |
| 8:58587617:CA:C | donor_gain | 1.0000 |
| 8:58589874:T:C | donor_gain | 1.0000 |
| 8:58594286:CTGCT:C | acceptor_gain | 1.0000 |
| 8:58595558:A:AC | donor_gain | 1.0000 |
| 8:58595558:ACT:A | donor_gain | 1.0000 |
| 8:58595559:C:CT | donor_gain | 1.0000 |
| 8:58595559:CT:C | donor_gain | 1.0000 |
| 8:58595559:CTC:C | donor_gain | 1.0000 |
| 8:58595559:CTCT:C | donor_gain | 1.0000 |
| 8:58595588:A:C | donor_gain | 1.0000 |
| 8:58595657:CAC:C | acceptor_gain | 1.0000 |
| 8:58595659:CCTG:C | acceptor_loss | 1.0000 |
| 8:58595660:C:CC | acceptor_gain | 1.0000 |
| 8:58595660:C:CG | acceptor_loss | 1.0000 |
| 8:58595661:T:A | acceptor_loss | 1.0000 |
| 8:58597436:TTTAA:T | donor_gain | 1.0000 |
| 8:58597901:TA:T | acceptor_gain | 1.0000 |
| 8:58597903:C:CC | acceptor_gain | 1.0000 |
| 8:58599257:C:CA | donor_gain | 1.0000 |
| 8:58599748:A:AC | donor_gain | 1.0000 |
| 8:58599749:C:CT | donor_gain | 1.0000 |
| 8:58599749:CT:C | donor_gain | 1.0000 |
| 8:58599866:ATTAA:A | acceptor_gain | 1.0000 |
AlphaMissense
6107 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 8:58597499:A:C | F560L | 1.000 |
| 8:58597499:A:T | F560L | 1.000 |
| 8:58597501:A:G | F560L | 1.000 |
| 8:58597497:C:T | G561E | 0.999 |
| 8:58599292:A:G | W509R | 0.999 |
| 8:58599292:A:T | W509R | 0.999 |
| 8:58599973:T:A | K443N | 0.999 |
| 8:58599973:T:G | K443N | 0.999 |
| 8:58599974:T:A | K443I | 0.999 |
| 8:58601296:T:A | R423S | 0.999 |
| 8:58601296:T:G | R423S | 0.999 |
| 8:58601297:C:G | R423T | 0.999 |
| 8:58601309:T:A | D419V | 0.999 |
| 8:58601310:C:G | D419H | 0.999 |
| 8:58601449:C:A | R404S | 0.999 |
| 8:58601449:C:G | R404S | 0.999 |
| 8:58601450:C:A | R404M | 0.999 |
| 8:58601450:C:G | R404T | 0.999 |
| 8:58601491:A:C | S390R | 0.999 |
| 8:58601491:A:T | S390R | 0.999 |
| 8:58601493:T:G | S390R | 0.999 |
| 8:58601503:G:C | F386L | 0.999 |
| 8:58601503:G:T | F386L | 0.999 |
| 8:58601505:A:G | F386L | 0.999 |
| 8:58603243:A:G | W338R | 0.999 |
| 8:58603243:A:T | W338R | 0.999 |
| 8:58603281:C:G | R325P | 0.999 |
| 8:58603340:C:A | W305C | 0.999 |
| 8:58603340:C:G | W305C | 0.999 |
| 8:58603342:A:G | W305R | 0.999 |
dbSNP variants (sampled 300 via entrez): RS1000130367 (8:58652132 T>C), RS1000162429 (8:58655499 G>A), RS1000264512 (8:58612766 C>A,T), RS1000296121 (8:58655247 C>T), RS1000328957 (8:58643222 C>T), RS1000355814 (8:58629774 T>A,C), RS1000378101 (8:58622514 C>T), RS1000401865 (8:58598273 G>C), RS1000410775 (8:58622860 G>A), RS1000419218 (8:58606535 C>T), RS1000497984 (8:58656398 A>C), RS1000503151 (8:58614314 A>G), RS1000535432 (8:58607581 A>G), RS1000553694 (8:58635910 C>A), RS1000558921 (8:58598504 A>C,G)
Disease associations
OMIM: gene MIM:603043 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
3 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST009066_15 | Mosaic loss of chromosome Y (Y chromosome dosage) | 4.000000e-08 |
| GCST012189_9 | Systolic blood pressure and diastolic blood pressure (bivariate analysis) | 6.000000e-06 |
| GCST90002379_120 | Basophil count | 2.000000e-09 |
EFO canonical traits (4, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007783 | mosaic loss of chromosome Y measurement |
| EFO:0006335 | systolic blood pressure |
| EFO:0006336 | diastolic blood pressure |
| EFO:0005090 | basophil count |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
GtoPdb / IUPHAR curated pharmacology
(IUPHAR/BPS Guide to Pharmacology — expert-curated)
Target class: enzyme — Neutral sphingomyelinase coupling factors
CTD chemical–gene interactions
44 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects cotreatment, decreases expression, affects expression | 7 |
| trichostatin A | affects expression, increases expression | 2 |
| (+)-JQ1 compound | affects expression, increases reaction, decreases expression | 2 |
| Benzo(a)pyrene | decreases expression | 2 |
| Doxorubicin | decreases expression, affects response to substance | 2 |
| aristolochic acid I | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| pirinixic acid | affects binding, increases activity, increases expression | 1 |
| bisphenol A | affects cotreatment, decreases methylation | 1 |
| arsenite | affects binding, increases reaction | 1 |
| sodium arsenite | increases expression | 1 |
| propionic acid | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| perfluoro-n-nonanoic acid | increases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| entinostat | decreases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, decreases expression | 1 |
| ICG 001 | increases expression | 1 |
| Grape Seed Proanthocyanidins | affects cotreatment, increases expression | 1 |
| dorsomorphin | affects cotreatment, decreases expression | 1 |
| Irinotecan | decreases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Sunitinib | increases expression | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Vorinostat | decreases expression | 1 |
| Panobinostat | affects expression, increases reaction | 1 |
| Air Pollutants | increases expression, increases abundance | 1 |
| Atrazine | decreases expression | 1 |
| Benzene | increases expression | 1 |
Cellosaurus cell lines
1 cell lines: 1 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_W802 | PC-53 | Cancer cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.